Eli Lilly will try to overturn the German Court of Appeal's ruling that its vitamin regimen patent for Alimta (pemetrexed) will not be infringed when Actavis launches a dipotassium salt form of pemetrexed after the cancer drug's compound patent expires in Germany in December.
The appellate court ruling, which reversed an April 2014 decision from the Regional Court of Dusseldorf, was announced on 6...
Welcome to Scrip
Create an account to read this article
Already a subscriber?